Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 8:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 215 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo1 Clear all
Terminated Phase 2 Interventional Results available

Rho Kinase (ROCK) Inhibition in Carotid Atherosclerosis

NCT00670202
View directory record Official record
Conditions
Carotid Stenosis
Interventions
Fasudil Hydrochloride, Placebo Oral Tablet
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 20, 2026, 8:51 AM EDT
Active, not recruiting Phase 2 Interventional

Probiotics to Prevent Relapse After Hospitalization for Bipolar Depression

NCT03349528
View directory record Official record
Conditions
Bipolar Depression
Interventions
Probiotic Supplement, Inert Compound
Biological
Lead sponsor
Sheppard Pratt Health System
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Towson, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 20, 2026, 8:51 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Signaling Mechanisms and Vascular Function in Patients With Diabetes Mellitus

NCT00762671
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions
Ebselen, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 30, 2008 · Synced Oct 20, 2026, 8:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

"Fermented Dairy Beverage on Inflammation/Immune Function in Stressful Exercise"

NCT03099044
View directory record Official record
Conditions
Healthy Subjects
Interventions
Placebo comparator, Single Active dose, Double Active dose
Other
Lead sponsor
Dairy A Day, Inc.
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 5, 2018 · Synced Oct 20, 2026, 8:51 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Pilot Study of Minocycline in Huntington's Disease

NCT00277355
View directory record Official record
Conditions
Huntington Disease
Interventions
minocycline, Matching placebo
Drug
Lead sponsor
Merit Cudkowicz
Network
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
11
States / cities
Birmingham, Alabama • Englewood, Colorado • Gainesville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2013 · Synced Oct 20, 2026, 8:51 AM EDT
Completed Phase 1 Interventional

Effect of SAR302503 on ECG Activity in Patients With Solid Tumors

NCT01836705
View directory record Official record
Conditions
Neoplasm Malignant
Interventions
SAR302503 (TG101348), Placebo SAR302503, Panolosetron
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
8
States / cities
Los Angeles, California • Augusta, Georgia • Detroit, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Oct 20, 2026, 8:51 AM EDT
Completed Phase 3 Interventional Results available

Tapentadol IR vs Oxycodone IR vs Placebo in Acute Pain From Vertebral Compression Fracture Associated With Osteoporosis

NCT00771758
View directory record Official record
Conditions
Back Pain
Interventions
oxycodone IR, placebo, tapentadol IR
Drug
Lead sponsor
Ortho-McNeil Janssen Scientific Affairs, LLC
Industry
Eligibility
50 Years to 85 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
37
States / cities
Haleyville, Alabama • Tallassee, Alabama • Peoria, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 20, 2026, 8:51 AM EDT
Completed Phase 2 Interventional Results available

A Study of CRV431 Dosed Once Daily in NASH Induced F2 and F3 Subjects

NCT04480710
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis, Fibrosis, Liver, NAFLD - Nonalcoholic Fatty Liver Disease
Interventions
CRV431 75mg, Placebo (1 softgel), CRV431 225mg, Placebo (3 softgels)
Drug
Lead sponsor
Hepion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
9
States / cities
Orange, California • Poway, California • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2022 · Synced Oct 20, 2026, 8:51 AM EDT
Completed Phase 4 Interventional Results available

Trial of Azithromycin vs. Doxycycline for the Treatment of Rectal Chlamydia in MSM

NCT03608774
View directory record Official record
Conditions
Anal Chlamydia Infection
Interventions
Azithromycin, Doxycycline, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years · Male only
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Boston, Massachusetts • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 7, 2021 · Synced Oct 20, 2026, 8:51 AM EDT
Completed Phase 4 Interventional Results available

Efficacy of Losartan in Preventing Progression of COPD

NCT00720226
View directory record Official record
Conditions
COPD, Emphysema, Chronic Bronchitis, Smoking
Interventions
Losartan, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Oct 20, 2026, 8:51 AM EDT
Terminated Phase 3 Interventional Results available

Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)

NCT00449150
View directory record Official record
Conditions
Benign Prostatic Hypertrophy
Interventions
Cetrorelix 78 mg + 78 mg, Cetrorelix 78 mg + 52 mg, Placebo
Drug
Lead sponsor
AEterna Zentaris
Industry
Eligibility
50 Years and older · Male only
Enrollment
667 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
46
States / cities
Huntsville, Alabama • Fort Smith, Arkansas • Laguna Hills, California + 39 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2018 · Synced Oct 20, 2026, 8:51 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Study to Evaluate Safety and Efficacy of ALX-0061 in Subjects With Systemic Lupus Erythematosus

NCT02437890
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
ALX-0061, Placebo
Biological
Lead sponsor
Ablynx, a Sanofi company
Industry
Eligibility
18 Years to 64 Years
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
28
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 20, 2026, 8:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, and Fecal Pharmacokinetics of BX002-A in Healthy Adults

NCT04737876
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BX002-A, Placebo
Biological · Other
Lead sponsor
BiomX, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 25, 2022 · Synced Oct 20, 2026, 8:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of ACP-196 on the Heart Rate-corrected QT Interval in Healthy Adult Participants

NCT04867980
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ACP-196, Moxifloxacin 400 mg, Placebo
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 30, 2021 · Synced Oct 20, 2026, 8:51 AM EDT
Withdrawn Phase 2 Interventional

Intramuscular Ketamine for Suicidal Ideation

NCT05105061
View directory record Official record
Conditions
Suicidal Ideation
Interventions
Ketamine (Ketalar), Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 5, 2022 · Synced Oct 20, 2026, 8:51 AM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Prevention of Severe Postpartum Hypertension

NCT02450773
View directory record Official record
Conditions
Hypertension
Interventions
Furosemide, Potassium chloride, Placebo #1, Placebo #2
Drug
Lead sponsor
Indiana University
Other
Eligibility
Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2022
U.S. locations
2
States / cities
Indianapolis, Indiana • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 11, 2023 · Synced Oct 20, 2026, 8:51 AM EDT
Withdrawn Phase 4 Interventional

Ramelteon vs Placebo for Prevention of Delirium and Improvement of Sleep in Hospitalized Older Adults

NCT03165695
View directory record Official record
Conditions
Delirium in Old Age
Interventions
Ramelteon, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
65 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 22, 2020 · Synced Oct 20, 2026, 8:51 AM EDT
Withdrawn Phase 2 Interventional

Chronic Fatigue Syndrome: A Presumptive Mitochondrial Disorder

NCT01471652
View directory record Official record
Conditions
Chronic Fatigue Syndrome
Interventions
Nutraceutical supplements, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
25 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2015 · Synced Oct 20, 2026, 8:51 AM EDT
Completed Phase 4 Interventional Results available

Effect of Saxagliptin on EPCs as a Cellular Biomarker for Evaluating Endothelial Dysfunction in Early T2DM Patients

NCT02024477
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Saxagliptin, Placebo
Drug
Lead sponsor
George Washington University
Other
Eligibility
40 Years to 70 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 20, 2026, 8:51 AM EDT
Not listed Phase 4 Interventional

Effect of Evolocumab in Patients With Critical Limb Ischemia (Evol-CLI)

NCT04306471
View directory record Official record
Conditions
Critical Limb Ischemia
Interventions
Evolocumab 140mg/mL Injector 1milliliter (mL) Pen x 3 for a monthly dose of 420 mg for 12 months., Placebo 1 milliliter (mL) Injector Pen x 3 monthly for 12 months
Drug · Other
Lead sponsor
Leonardo Clavijo
Other
Eligibility
40 Years to 85 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 13, 2020 · Synced Oct 20, 2026, 8:51 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane

NCT03384563
View directory record Official record
Conditions
Pediatric Anesthesia
Interventions
Dexmedetomidine
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Month to 36 Months
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Oct 20, 2026, 8:51 AM EDT
Recruiting Phase 2 Interventional

4-Aminopyridine to Treat Skin Burns

NCT06596434
View directory record Official record
Conditions
Burns, Second Degree Burn, Wounds and Injuries
Interventions
Drug: 4-Aminopyridine, Placebo
Drug · Other
Lead sponsor
John Elfar
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 20, 2026, 8:51 AM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)

NCT06799000
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Remibrutinib Dose A, Remibrutinib Dose B, Placebo 1, Placebo 2
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 100 Years
Enrollment
588 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
36
States / cities
Phoenix, Arizona • Fort Smith, Arkansas • North Little Rock, Arkansas + 32 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 20, 2026, 8:51 AM EDT
Not yet recruiting Phase 2 Interventional

Tiprelestat Versus Placebo When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension (PAH)

NCT07601295
View directory record Official record
Conditions
Pulmonary Arterial Hypertension (PAH)
Interventions
Tiprelestat (5 mg), Placebo (1 mL 0.9% saline solution), Tiprelestat (10 mg)
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
10
States / cities
Tucson, Arizona • San Francisco, California • Stanford, California + 7 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 20, 2026, 8:51 AM EDT